The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $392.55

Today's change-2.67 -0.68%
Updated August 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $392.55

Today's change-2.67 -0.68%
Updated August 31 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc crosses below 50-day moving average

Regeneron Pharmaceuticals Inc closed lower Wednesday, dropping (U.S.)$2.67 or 0.68% to (U.S.)$392.55 and crossing below its 50-day moving average. Over the last five days, shares have lost 3.13% and are down 27.69% for the last year to date. This security has underperformed the S&P 500 by 33.63% during the last year.

Key company metrics

  • Open(U.S.) $396.01
  • Previous close(U.S.) $395.22
  • High(U.S.) $397.27
  • Low(U.S.) $390.02
  • Bid / Ask(U.S.) $390.00 / (U.S.) $401.00
  • YTD % change-27.69%
  • Volume568,911
  • Average volume (10-day)628,488
  • Average volume (1-month)743,102
  • Average volume (3-month)851,390
  • 52-week range(U.S.) $329.09 to (U.S.) $592.59
  • Beta1.24
  • Trailing P/E61.28×
  • P/E 1 year forward36.15×
  • Forward PEG1.94×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.41
Updated August 31 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.59%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue1,2131,2011,0981,137
Total other revenue--------
Total revenue1,2131,2011,0981,137
Gross profit1,1441,0899871,028
Total cost of revenue69112111109
Total operating expense921872869745
Selling / general / administrative292290295210
Research & development560470461426
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----20
Other operating expenses, total--------
Operating income292329229392
Interest income (expense), net non-operating-----4-2
Gain (loss) on sale of assets--------
Other--------
Income before tax292330227393
Income after tax196181155210
Income tax, total9614972183
Net income196181155210
Total adjustments to net income--------
Net income before extra. items196181155210
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items196181155210
Inc. avail. to common incl. extra. items196181155210
Diluted net income196182155210
Dilution adjustment000--
Diluted weighted average shares116116115116
Diluted EPS excluding extraordinary itemsvalue per share1.691.561.341.81
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.691.561.351.81